Several studies have indicated that altered serotonergic neurotransmission may contribute to non-motor features commonly associated with Parkinson's disease (PD) such as apathy and depression.The 5-Hydroxytryptophan (5-HTP) is the intermediate metabolite of L-tryptophan in the production of serotonin. To date, there has been inconsistent research on the use of 5-HTP in PD. The purpose of this study was to compare the effects of 5-HTP to placebo on apathy and depressive symptoms in patients with PD.
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Parkinson's disease: a preliminary finding
Meloni, Mario;Puligheddu, Monica;Carta, Manolo;Figorilli, Michela;Defazio, GiovanniUltimo
2020-01-01
Abstract
Several studies have indicated that altered serotonergic neurotransmission may contribute to non-motor features commonly associated with Parkinson's disease (PD) such as apathy and depression.The 5-Hydroxytryptophan (5-HTP) is the intermediate metabolite of L-tryptophan in the production of serotonin. To date, there has been inconsistent research on the use of 5-HTP in PD. The purpose of this study was to compare the effects of 5-HTP to placebo on apathy and depressive symptoms in patients with PD.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2020 Efficacy and safety.pdf
Solo gestori archivio
Tipologia:
versione editoriale (VoR)
Dimensione
362.24 kB
Formato
Adobe PDF
|
362.24 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
